Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

被引：0
|
作者：
Alison R Meloni
Mary Beth DeYoung
Jenny Han
Jennie H Best
Michael Grimm
机构：
[1] Amylin Pharmaceuticals,
[2] LLC,undefined
来源：
Cardiovascular Diabetology | / 12卷
关键词：
Number needed to treat; Absolute benefit; Exenatide; Type 2 diabetes; Diabetes mellitus; ADA treatment guidelines; GLP-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
    Meloni, Alison R.
    DeYoung, Mary Beth
    Han, Jenny
    Best, Jennie H.
    Grimm, Michael
    CARDIOVASCULAR DIABETOLOGY, 2013, 12
  • [2] Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk factors in subjects with type 2 diabetes
    Diamant, M.
    Van Gaal, L. F.
    Stranks, S. N.
    Northrup, J.
    Cao, D.
    Taylor, K.
    Trautmann, M.
    DIABETOLOGIA, 2010, 53
  • [3] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Bargiota, Alexandra
    Kourlaba, Georgia
    Gourzoulidis, George
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 67 - 77
  • [4] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [5] Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Alexandra Bargiota
    Georgia Kourlaba
    George Gourzoulidis
    Nikos Maniadakis
    Clinical Drug Investigation, 2018, 38 : 67 - 77
  • [6] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Rozalina G. McCoy
    Jeph Herrin
    Kavya Sindhu Swarna
    Yihong Deng
    David M. Kent
    Joseph S. Ross
    Guillermo E. Umpierrez
    Rodolfo J. Galindo
    William H. Crown
    Bijan J. Borah
    Victor M. Montori
    Juan P. Brito
    Joshua J. Neumiller
    Mindy M. Mickelson
    Eric C. Polley
    Nature Cardiovascular Research, 2024, 3 : 431 - 440
  • [7] Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
    Mccoy, Rozalina G.
    Herrin, Jeph
    Swarna, Kavya Sindhu
    Deng, Yihong
    Kent, David M.
    Ross, Joseph S.
    Umpierrez, Guillermo E.
    Galindo, Rodolfo J.
    Crown, William H.
    Borah, Bijan J.
    Montori, Victor M.
    Brito, Juan P.
    Neumiller, Joshua J.
    Mickelson, Mindy M.
    Polley, Eric C.
    NATURE CARDIOVASCULAR RESEARCH, 2024, 3 (04): : 431 - 440
  • [8] Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
    Patti, Angelo Maria
    Rizvi, Ali A.
    Giglio, Rosaria Vincenza
    Stoian, Anca Pantea
    Ligi, Daniela
    Mannello, Ferdinando
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [9] Glycemic and Weight Lowering Effects of Exenatide Once Weekly Are Associated with Blood Pressure Changes in Patients with Type 2 Diabetes
    Paul, Sanjoy
    Best, Jennie H.
    Klein, Kerenaftali
    Han, Jenny
    Maggs, David
    DIABETES, 2011, 60 : A296 - A296
  • [10] Efficacy and safety of insulin lispro protamine suspension versus insulin glargine added to oral antihyperglycaemic medications and exenatide in patients with type 2 diabetes
    Arakaki, R. F.
    Blevins, T. C.
    Liljenquist, D. R.
    Wise, J. K.
    Jiang, H. H.
    Schneider, K. K.
    Jacobson, J. G.
    Martin, S. A.
    Jackson, J. A.
    DIABETOLOGIA, 2010, 53
12345